伏硫西汀对抑郁症疗效、认知功能和BDNF影响的研究进展  

Research progress of vortioxetine on depression efficacy, cognitive function and BDNF

作　　者：矫健萍 胡健波[1] 黄满丽[1] JIAO Jianping;HU Jianbo;HUANG Manli(Department of Psychiatry,the First Affiliated Hospital,Zhejiang University School of Medicine,The Key Laboratory of Mental Disorder Management in Zhejiang Province,Brain Research Institute of Zhejiang University,Zhejiang Engineering Center for Mathematical Mental Health,Hangzhou310003,China)

机构地区：[1]浙江大学医学院附属第一医院精神卫生科/浙江省精神障碍诊疗和防治技术重点实验室/浙江大学脑科研究所/数理心理健康浙江省工程研究中心,浙江杭州310003

出　　处：《中国现代医生》2020年第9期184-188,共5页China Modern Doctor

基　　金：浙江省重点研发计划项目(2015C03040);浙江省分析测试科技计划项目(2018C37064)。

摘　　要：抑郁症作为常见精神障碍,患病率高、复发率高、自杀率高、疾病负担重,临床主要表现为情绪低落、兴趣减退、快感缺乏,认知功能损害等症状。近年来抑郁症的认知功能损害症状受到广泛关注。认知损害不仅存在于抑郁症急性期,而且还可以作为残留症状持续至缓解期,残留的认知障碍是导致抑郁症复发的最主要因素之一,所以迫切需要既能改善抑郁情绪又能改善认知损害的药物。2017年在中国上市的伏硫西汀是一种多模式新型抗抑郁药,在改善抑郁的同时可以改善认知症状,还可以调节血浆及脑内脑源性神经营养因子(brain derived neu rotrophic factor,BDNF)的水平上升高。本文旨对近年伏硫西汀对抑郁症的疗效、认知功能和对BDNF影响的研究进展进行综述。Depression, as a common mental disorder, features high prevalence, high relapse rate, high suicide rate, and heavy burden. The clinical manifestations are mainly depression, decreased interest, lack of pleasure, cognitive impairment and so on. In recent years, the symptoms of cognitive impairment in depression have received wide attention,since it not only exists in the acute phase of depression, but also can be a residual symptom to the remission period.Residual cognitive impairment is one of the most important factors leading to the recurrence of depression. Therefore, it is urgent to develop drugs that can both improve depression and cognitive impairment. Vortioxetine entering circulation in China in 2017 is a new multi-mode antidepressant, which can improve cognitive symptoms and depression, and can also regulate plasma and increase brain derived neurotrophic factor(BDNF) levels. This paper aims to review research progress of vortioxetine on depression, cognitive function and BDNF in recent years.

关 键 词：抑郁症 伏硫西汀 认知功能 脑源性神经营养因子 

分 类 号：R749.4[医药卫生—神经病学与精神病学]